These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36842303)

  • 1. Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab.
    Damato V; Spagni G; Monte G; Scandiffio L; Cavalcante P; Zampetti N; Fossati M; Falso S; Mantegazza R; Battaglia A; Fattorossi A; Evoli A
    Neuromuscul Disord; 2023 Mar; 33(3):288-294. PubMed ID: 36842303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
    Reyes-Leiva D; López-Contreras J; Moga E; Pla-Juncà F; Lynton-Pons E; Rojas-Garcia R; Turon-Sans J; Querol L; Olive M; Álvarez-Velasco R; Caballero-Ávila M; Carbayo Á; Vesperinas-Castro A; Domingo P; Illa I; Gallardo E; Cortés-Vicente E
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35728947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
    Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
    Front Immunol; 2022; 13():834981. PubMed ID: 35154159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.
    Taus E; Hofmann C; Ibarrondo FJ; Gong LS; Hausner MA; Fulcher JA; Krogstad P; Kitchen SG; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
    Front Immunol; 2023; 14():1100594. PubMed ID: 36860850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
    Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
    Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
    Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
    PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy.
    Hodl I; Sallegger C; Forstner P; Sareban N; Moritz M; Dreo B; Schulz E; Lackner A; Kleinhappl B; Hatzl S; Moazedi-Fürst F; Seifert-Held T; Heschl B; Khalil M; Enzinger C; Greinix H; Stradner MH; Steinmetz I; Schlenke P; Fessler J
    Microbes Infect; 2023 May; 25(4):105103. PubMed ID: 36681177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
    Fabris M; De Marchi G; Domenis R; Caponnetto F; Guella S; Dal Secco C; Cabas N; De Vita S; Beltrami AP; Curcio F; Quartuccio L
    J Autoimmun; 2022 May; 129():102827. PubMed ID: 35427999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.
    Rizzo R; Bortolotti D; Morandi L; Rizzo S; Schiuma G; Beltrami S; Papi A; Contoli M
    Int J Infect Dis; 2022 Sep; 122():412-414. PubMed ID: 35750264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab.
    Bacova B; Kohutova Z; Zubata I; Gaherova L; Kucera P; Heizer T; Mikesova M; Karel T; Novak J
    Clin Exp Med; 2023 Jun; 23(2):371-379. PubMed ID: 35352210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment.
    Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
    Riise J; Meyer S; Blaas I; Chopra A; Tran TT; Delic-Sarac M; Hestdalen ML; Brodin E; Rustad EH; Dai KZ; Vaage JT; Nissen-Meyer LSH; Sund F; Wader KF; Bjornevik AT; Meyer PA; Nygaard GO; König M; Smeland S; Lund-Johansen F; Olweus J; Kolstad A
    Br J Haematol; 2022 Jun; 197(6):697-708. PubMed ID: 35254660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature.
    Ramdas S; Hum RM; Price A; Paul A; Bland J; Burke G; Farrugia M; Palace J; Storrie A; Ho P; Standing E; Lilleker JB; Jungbluth H
    Neuromuscul Disord; 2022 Oct; 32(10):785-789. PubMed ID: 36130855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
    Madelon N; Lauper K; Breville G; Sabater Royo I; Goldstein R; Andrey DO; Grifoni A; Sette A; Kaiser L; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
    Clin Infect Dis; 2022 Aug; 75(1):e1037-e1045. PubMed ID: 34791081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.